

Date: 24th July 2025
Ref: CORP 25/26 - 071

Dear xxx

Freedom of Information request: Endometrial Cancer (CORP 25/26 – 071)

Thank you for your request for information which the Trust received on 4th July 2025

Your Request:

Q1. Does your trust provide SACT (systemic anti-cancer therapy) treatments for endometrial cancer? If not, which other trust do you refer endometrial cancer patients to for SACT treatments?

Q2. How many patients were treated for endometrial cancer (any stage) in the past three months with the following treatments:

- *Dostarlimab (Jemperli)*
- *Dostarlimab (Jemperli) AND Chemotherapy*
- *Hormone therapy (Progesterone or Letrozole)*
- *Pembrolizumab (Keytruda) monotherapy*
- *Lenvatinib + Pembrolizumab (Lenvima +Keytruda)*
- *Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)*
- *Any other SACT*
- *Any other Chemotherapy*
- *Durvalumab with platinum-based chemotherapy*
- *Pembrolizumab with platinum-based chemotherapy*


Q3. Does your trust participate in any clinical trials for the treatment of endometrial cancer? If so, can you please provide the name of each trial and the number of patients taking part?

Please find the Trust's response below:

Q1. Does your trust provide SACT (systemic anti-cancer therapy) treatments for endometrial cancer? If not, which other trust do you refer endometrial cancer patients to for SACT treatments?

Yes

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.
Velindre University NHS Trust is happy to receive communication in Welsh or English.



Q2. How many patients were treated for endometrial cancer (any stage) in the past three months with the following treatments:

- Dostarlimab (Jemperli)
- Dostarlimab (Jemperli) AND Chemotherapy
- Hormone therapy (Progesterone or Letrozole)
- Pembrolizumab (Keytruda) monotherapy
- Lenvatinib + Pembrolizumab (Lenvima +Keytruda)
- Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)
- Any other SACT
- Any other Chemotherapy
- Durvalumab with platinum-based chemotherapy
- Pembrolizumab with platinum-based chemotherapy

The Trust does not record the data requested in a format that enables the information to be easily retrieved to the level of detail required to specifically answer your request.

In reaching this decision we estimate that it would take a minimum of 22 hours or £550, which is an additional amount of £100 over the core amount of £450 to obtain the data. The amount would require payment in full prior to the Trust undertaking the work.

As result, the Trust is applying an exemption under Section 12 Freedom of Information Act (Exemption where cost of compliance exceeds appropriate limit), the legislation in this instance states:

12 Exemption where cost of compliance exceeds appropriate limit.


(1) Section 1(1) does not oblige a public authority to comply with a request for information if the authority estimates that the cost of complying with the request would exceed the appropriate limit.

The Trust has a duty to advise and assist you under Section 16 of the Act and therefore may I suggest that you consider the option to revise your request so that it falls below the prescribed appropriate limit.

Q3. Does your trust participate in any clinical trials for the treatment of endometrial cancer? If so, can you please provide the name of each trial and the number of patients taking part?

Velindre University NHS Trust is currently participating in the following clinical trials for the treatment of endometrial cancer:

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.
Velindre University NHS Trust is happy to receive communication in Welsh or English.



1. **DOMENICA Study**

Full title: Randomized phase III trial in MMR-deficient endometrial cancer patients comparing chemotherapy alone versus Dostarlimab in first-line advanced / metastatic setting (GINECO-EN105b/ENGOT-en13)

Number of participants recruited: <6*

2. **AtTEnd Study**

Full title: Atezolizumab in Endometrial Cancer

Number of participants recruited: 7

*Where the figure provided is less than 6, and where simple calculations could identify fields that contain less than 6, the Trust has applied an exemption under Section 40(2) (personal data) of the Freedom of Information Act 2000. This is because the Trust believes there is a potential risk of individuals being able to be identified if the figures were disclosed.

I trust this answers your request for information, however, should you not be satisfied with the information supplied or the process of supplying it, you have a right to complain and request a review. Please note that you must submit a request for a review within 40 days of the date of this letter.


You should forward your complaint to:

Mr Ian Bevan via FOI.VUNHST@wales.nhs.uk
Head of Information Governance
Velindre University NHS Trust
2, Charnwood Court
Heol Billingsley
Parc Nantgarw
Cardiff
CF15 7QZ

Should you wish to take your complaint further, if you are still unhappy with the decision after review, you can contact the:

Information Commissioner's Office - Wales
2nd Floor, Churchill House
Churchill Way
Cardiff
CF10 2HH
Telephone: 0330 414 6421
email: wales@ico.org.uk

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.
Velindre University NHS Trust is happy to receive communication in Welsh or English.



Yours sincerely

Non Gwilym
Interim Director of Corporate Governance
Velindre University NHS Trust
2 Charnwood Court
Heol Billingsley
Parc Nantgarw
Cardiff
CF15 7QZ

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.
Velindre University NHS Trust is happy to receive communication in Welsh or English.

